


## NCTN Myeloma Trials Portfolio (Open as of 1/15/2022)

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



### Cross-disease trials:

EAY131 (MATCH)

S1609 (DART)

## NCTN Myeloma Trials (Open as of 1/15/2022)

Protocol Number	Phase	Protocol Title
EAA171	III	Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
EAA173	III	Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
EAA181	III	Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
S1803	III	Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
EAY131	II	Molecular Analysis for Therapy Choice (MATCH)
S1609	II	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors